Eagle Asset Management Inc. cut its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 2.6% during the first quarter, Holdings Channel reports. The institutional investor owned 237,371 shares of the biopharmaceutical company’s stock after selling 6,459 shares during the period. Eagle Asset Management Inc.’s holdings in Emergent Biosolutions were worth $6,893,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the stock. Hodges Capital Management Inc. acquired a new stake in Emergent Biosolutions during the fourth quarter worth about $1,084,000. FMR LLC increased its stake in Emergent Biosolutions by 39.7% in the fourth quarter. FMR LLC now owns 288,348 shares of the biopharmaceutical company’s stock worth $9,469,000 after buying an additional 81,898 shares in the last quarter. New York State Common Retirement Fund increased its stake in Emergent Biosolutions by 48.2% in the third quarter. New York State Common Retirement Fund now owns 109,712 shares of the biopharmaceutical company’s stock worth $3,459,000 after buying an additional 35,707 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Emergent Biosolutions during the fourth quarter worth about $14,824,000. Finally, Acadian Asset Management LLC increased its stake in Emergent Biosolutions by 1.4% in the first quarter. Acadian Asset Management LLC now owns 1,400,091 shares of the biopharmaceutical company’s stock worth $40,658,000 after buying an additional 18,739 shares in the last quarter. 89.61% of the stock is owned by hedge funds and other institutional investors.
Shares of Emergent Biosolutions Inc (NYSE:EBS) traded down 0.98% during trading on Monday, hitting $29.45. 225,611 shares of the stock traded hands. The stock has a 50-day moving average of $29.68 and a 200 day moving average of $30.19. Emergent Biosolutions Inc has a 1-year low of $24.47 and a 1-year high of $44.38. The company has a market cap of $1.21 billion, a P/E ratio of 23.41 and a beta of 1.02.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by $0.08. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. The firm had revenue of $116.90 million during the quarter, compared to the consensus estimate of $121.30 million. During the same quarter last year, the business posted $0.16 earnings per share. Emergent Biosolutions’s revenue was up 13.5% compared to the same quarter last year. On average, equities research analysts predict that Emergent Biosolutions Inc will post $1.58 EPS for the current fiscal year.
A number of analysts have issued reports on EBS shares. Chardan Capital reissued a “buy” rating and issued a $47.00 price objective on shares of Emergent Biosolutions in a report on Monday, January 30th. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Wednesday, February 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Emergent Biosolutions currently has a consensus rating of “Buy” and a consensus target price of $39.40.
In other news, EVP Adam Havey sold 11,419 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $28.62, for a total value of $326,811.78. Following the completion of the transaction, the executive vice president now directly owns 26,046 shares in the company, valued at $745,436.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jerome M. Hauer sold 2,576 shares of the firm’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $31.27, for a total transaction of $80,551.52. Following the completion of the transaction, the director now owns 17,404 shares of the company’s stock, valued at $544,223.08. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by company insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/emergent-biosolutions-inc-ebs-position-cut-by-eagle-asset-management-inc/1843353.html
Receive News & Ratings for Emergent Biosolutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.